Table 1 Baseline demographic and clinical characteristics of the intention-to-treat population
Variable | Placebo + MTX (n = 398) | Sarilumab 150 mg q2w + MTX (n = 400) | Sarilumab 200 mg q2w + MTX (n = 399) |
|---|---|---|---|
Age (years) | 50.9 ± 11.2 | 50.1 ± 11.9 | 50.8 ± 11.8 |
Female (%) | 80.7 | 79.8 | 84.5 |
Race (%) | |||
Caucasian | 86.2 | 86.3 | 86.0 |
Black | 2.5 | 2.5 | 2.0 |
Asian | 8.0 | 8.3 | 8.3 |
Other | 3.3 | 3.0 | 3.8 |
Region (%) | |||
Western Europe | 18.6 | 18.8 | 18.8 |
South America | 38.9 | 38.8 | 38.8 |
Rest of world | 42.5 | 42.5 | 42.4 |
RA duration (years) | 9.1 ± 8.1 | 9.5 ± 8.5 | 8.6 ± 7.0 |
Prior biologic DMARD use (%) | 20.6 | 20.5 | 19.5 |
Seropositive for rheumatoid factor (%) | 84.4 | 87.1 | 82.6 |
Anti-CCP antibody positive (%) | 85.4 | 90.2 | 84.9 |
Tender joint count | 26.8 ± 13.8 | 27.2 ± 14.2 | 26.5 ± 14.5 |
Swollen joint count | 16.7 ± 9.3 | 16.6 ± 9.0 | 16.8 ± 9.7 |
CRP (mg/dl) | 2.0 ± 2.3 | 2.4 ± 2.3 | 2.2 ± 2.4 |
DAS28-CRP | 5.9 ± 0.9 | 6.0 ± 0.9 | 6.0 ± 0.9 |
PtGA (VAS) | 63.7 ± 19.9 | 64.4 ± 20.4 | 66.3 ± 20.8 |
Pain VAS | 63.7 ± 19.9 | 65.4 ± 21.4 | 66.7 ± 21.4 |
HAQ-DI | 1.6 ± 0.7 | 1.6 ± 0.6 | 1.7 ± 0.6 |
FACIT-F | 27.2 ± 10.4 | 26.3 ± 9.8 | 25.9 ± 10.4 |
SF-36 PCS | 31.9 ± 6.9 | 31.5 ± 6.7 | 31.1 ± 6.8 |
SF-36 MCS | 38.9 ± 11.4 | 39.0 ± 11.3 | 38.7 ± 12.0 |